Wall Street brokerages forecast that Teva Pharmaceutical Industries Limited (NYSE:TEVA) will post $5.33 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $5.26 billion to $5.40 billion. Teva Pharmaceutical Industries posted sales of $6.49 billion in the same quarter last year, which would indicate a negative year over year growth rate of 17.9%. The company is scheduled to report its next earnings results on Monday, February 12th.

According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full year sales of $5.33 billion for the current year, with estimates ranging from $22.19 billion to $22.99 billion. For the next year, analysts expect that the firm will report sales of $20.40 billion per share, with estimates ranging from $19.62 billion to $22.43 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Teva Pharmaceutical Industries.

Several brokerages have weighed in on TEVA. ValuEngine upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Tuesday. Royal Bank Of Canada set a $11.00 price objective on Teva Pharmaceutical Industries and gave the company a “sell” rating in a research note on Wednesday, November 29th. Mizuho raised their price objective on Teva Pharmaceutical Industries from $12.00 to $16.00 and gave the company a “neutral” rating in a research note on Wednesday, November 29th. BTIG Research set a $16.00 price objective on Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Tuesday, November 28th. Finally, Cantor Fitzgerald set a $10.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Monday, November 27th. Seven equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $21.65.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Security National Bank of Sioux City Iowa IA increased its holdings in Teva Pharmaceutical Industries by 0.4% in the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock worth $724,000 after acquiring an additional 87 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its holdings in Teva Pharmaceutical Industries by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after acquiring an additional 94 shares during the last quarter. Sheaff Brock Investment Advisors LLC increased its holdings in Teva Pharmaceutical Industries by 3.6% in the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 8,389 shares of the company’s stock worth $279,000 after acquiring an additional 294 shares during the last quarter. IFP Advisors Inc increased its holdings in Teva Pharmaceutical Industries by 3.8% in the 2nd quarter. IFP Advisors Inc now owns 12,629 shares of the company’s stock worth $420,000 after acquiring an additional 459 shares during the last quarter. Finally, Bank of Nova Scotia increased its holdings in Teva Pharmaceutical Industries by 8.3% in the 2nd quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after acquiring an additional 528 shares during the last quarter. 52.05% of the stock is owned by institutional investors.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded up $1.05 during trading hours on Friday, reaching $16.05. The company’s stock had a trading volume of 22,508,018 shares, compared to its average volume of 15,675,085. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $38.31. The company has a market cap of $14,559.28, a PE ratio of 3.31 and a beta of 0.55.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 2.12%. The ex-dividend date of this dividend is Monday, November 27th. Teva Pharmaceutical Industries’s dividend payout ratio is presently -12.10%.

TRADEMARK VIOLATION NOTICE: “$5.33 Billion in Sales Expected for Teva Pharmaceutical Industries Limited (TEVA) This Quarter” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/12/08/5-33-billion-in-sales-expected-for-teva-pharmaceutical-industries-limited-teva-this-quarter.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.